Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure.
- Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure.
- The claims of the newly issued patent cover longer durations of istaroxime infusion for improved outcomes in treatment of acute heart failure.
- “Windtree continues to strengthen the patent estate for istaroxime with this new issuance from the USPTO,” said Craig Fraser, CEO and President of Windtree Therapeutics.
- We plan to continue this work to further expand istaroxime’s patent estate in the clinical development work ahead.”